GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
    Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy ; 2015
    In:  Mediterranean Journal of Hematology and Infectious Diseases Vol. 7 ( 2015-02-12), p. e2015015-
    Details
    In: Mediterranean Journal of Hematology and Infectious Diseases, Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy, Vol. 7 ( 2015-02-12), p. e2015015-
    Abstract: Classical Hodgkin lymphoma (cHL) is a relatively rare disease, with approximately 9,200 estimated new cases and 1,200 estimated deaths per year in the United States. First-line chemo-radiotherapy leads to cure rates approaching 80% in patients with advanced-stage disease. However, 25 to 30% of these patients are not cured with chemotherapy alone (i.e., the ABVD regimen) and show either primary refractoriness to chemotherapy, early disease relapse or late disease relapse. Second-line salvage high-dose chemotherapy (HDC) and autologous stem cell transplantation (SCT) have an established role in the management of refractory/relapsed cHL, leading to durable responses in approximately 50% of relapsed patients and a minority of refractory patients. However, due to the poor responses to second-line salvage chemotherapy and dismal long-term disease control of primary refractory and early relapsed patients, their treatment represents an unmet medical need. Allogeneic SCT represents, by far, the only strategy with a curative potential for these patients. Despite a general consensus that early relapsed and primary refractory patients represent a clinical challenge requiring effective treatments to achieve long-term disease control, there has been no consensus on the optimal therapy that should be offered to these patients. This review will briefly discuss the clinical results and the main issues regarding autologous SCT as well as the current role of allogeneic SCT.
    Type of Medium: Online Resource
    ISSN: 2035-3006
    URL: Article
    DOI: 10.4084/mjhid.2015.015
    Language: Unknown
    Publisher: Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy
    Publication Date: 2015
    detail.hit.zdb_id: 2674750-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study
    Ferrata Storti Foundation (Haematologica) ; 2023
    In:  Haematologica ( 2023-08-31)
    Details
    In: Haematologica, Ferrata Storti Foundation (Haematologica), ( 2023-08-31)
    Abstract: Therapies that demonstrate durable, long-term responses with manageable safety and tolerability are needed for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrrolobenzodiazepine dimer, demonstrated single-agent antitumor activity in the pivotal phase 2 LOTIS-2 study in heavily pretreated patients with R/R DLBCL. Here we present updated efficacy and safety analyses from LOTIS-2, performed for all patients and in subsets of patients with a complete response (CR), including patients with CR who were event-free (no progressive disease or death) for ≥1 year and ≥2 years from cycle 1, day 1 of treatment. Lonca was administered every 3 weeks (0.15 mg/kg for 2 cycles; 0.075 mg/kg for subsequent cycles). As of the final data cutoff (September 15, 2022; median follow-up: 7.8 months [range, 0.3-42.6] ), 70 of 145 (48.3%) patients achieved an overall response. Thirty-six (24.8%) patients achieved CR, of which 16 (44%) and 11 (31%) were event-free for ≥1 year and ≥2 years, respectively. In the all-treated population, the median overall survival was 9.5 months; the median progression-free survival was 4.9 months. Among patients with CR, median overall survival and progression-free survival were not reached, with 24-month overall and progression-free survival rates of 68.2% (95% CI: 50.0-81.0) and 72.5% (95% CI: 48.2-86.8), respectively. No new safety concerns were detected. With additional follow-up, Lonca continued to demonstrate durable, long-term responses with manageable safety and tolerability in patients with CR. This trial is registered at ClinicalTrials.gov (NCT03589469).
    Type of Medium: Online Resource
    ISSN: 1592-8721 , 0390-6078
    URL: Article
    DOI: 10.3324/haematol.2023.283459
    Language: Unknown
    Publisher: Ferrata Storti Foundation (Haematologica)
    Publication Date: 2023
    detail.hit.zdb_id: 2186022-1
    detail.hit.zdb_id: 2030158-3
    detail.hit.zdb_id: 2805244-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis
    Ferrata Storti Foundation (Haematologica) ; 2020
    In:  Haematologica Vol. 106, No. 1 ( 2020-01-16), p. 74-86
    Details
    In: Haematologica, Ferrata Storti Foundation (Haematologica), Vol. 106, No. 1 ( 2020-01-16), p. 74-86
    Abstract: Allogeneic hematopoietic stem cell transplantation is the treatment of choice for autosomal recessive osteopetrosis caused by defects in the TCIRG1 gene. Despite recent progress in conditioning, a relevant number of patients are not eligible for allogeneic stem cell transplantation because of the severity of the disease and significant transplant-related morbidity. We exploited peripheral CD34+ cells, known to circulate at high frequency in the peripheral blood of TCIRG1-deficient patients, as a novel cell source for autologous transplantation of gene corrected cells. Detailed phenotypical analysis showed that circulating CD34+ cells have a cellular composition that resembles bone marrow, supporting their use in gene therapy protocols. Transcriptomic profile revealed enrichment in genes expressed by hematopoietic stem and progenitor cells (HSPCs). To overcome the limit of bone marrow harvest/ HSPC mobilization and serial blood drawings in TCIRG1 patients, we applied UM171-based ex-vivo expansion of HSPCs coupled with lentiviral gene transfer. Circulating CD34+ cells from TCIRG1-defective patients were transduced with a clinically-optimized lentiviral vector (LV) expressing TCIRG1 under the control of phosphoglycerate promoter and expanded ex vivo. Expanded cells maintained long-term engraftment capacity and multi-lineage repopulating potential when transplanted in vivo both in primary and secondary NSG recipients. Moreover, when CD34+ cells were differentiated in vitro, genetically corrected osteoclasts resorbed the bone efficiently. Overall, we provide evidence that expansion of circulating HSPCs coupled to gene therapy can overcome the limit of stem cell harvest in osteopetrotic patients, thus opening the way to future gene-based treatment of skeletal diseases caused by bone marrow fibrosis.
    Type of Medium: Online Resource
    ISSN: 1592-8721 , 0390-6078
    URL: Article
    DOI: 10.3324/haematol.2019.238261
    Language: Unknown
    Publisher: Ferrata Storti Foundation (Haematologica)
    Publication Date: 2020
    detail.hit.zdb_id: 2186022-1
    detail.hit.zdb_id: 2030158-3
    detail.hit.zdb_id: 2805244-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    DEMOGRAPHICAL, VIRO-IMMUNOLOGICAL, CLINICAL AND THERAPEUTICAL CHARACTERISTICS OF HIV INFECTED PATIENTS IN A “EPIDEMIOLOGICALLY UNEXPLORED” REGION OF ITALY (CALABRIA REGION): THE CALABRHIV COHORT.
    Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy ; 2015
    In:  Mediterranean Journal of Hematology and Infectious Diseases Vol. 7 ( 2015-10-08), p. e2015054-
    Details
    In: Mediterranean Journal of Hematology and Infectious Diseases, Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy, Vol. 7 ( 2015-10-08), p. e2015054-
    Abstract: Background and Objectives HIV epidemics may differ among epidemiological contexts. We aimed at constructing an HIV clinical cohort whose main epidemiological, clinical and therapeutical characteristics are described (the CalabrHIV cohort, Calabria Region, Southern Italy). Methods The CalabrHIV cohort includes all HIV patients on active follow-up in all infectious disease centers in the Calabria Region as at October 2014. All information were recorded in a common electronic database. Not-infectious co-morbidities (such as cardiovascular diseases, bone fractures, diabetes, renal failure and hypertension) were also studied. Results 548 patients (68% males; 63% aged 〈 50 years) were included in the CalabrHIV cohort. Major risk factors: sexual transmission (49%) and intravenous drug use (34%). 39% patients had HCV and/or HBV co-infection. An high percentage of late presenters was observed (68.4% patients with CD4+ nadir 〈 350/mm3and 38.5% patients with AIDS at baseline). 83% patients on HAART  had actually undetectable HIV-RNA. Hypertension was the most frequent co-morbidity (21.5%). Multi-morbidity was more frequent in 〉 50 years-old patients than in 〈 50 years-old ones (30% vs. 6%; p 〈 0.0001). Co-morbidity was more frequent in HCV and/or HBV co-infected than in HIV mono-infected patients (46.6% vs. 31.7%: p=0.0006). Conclusion This cohort presentation study sheds light, for the first time, on HIV patients’ characteristics in the Calabria Region. Despite a small number of officially reported cases, the size of the cohort was substantial. We showed that HIV infected patients with chronic hepatites, were affected by concomitant not-infectious co-morbidities more than the HIV mono-infected individuals. New HCV treatments are eagerly awaited.
    Type of Medium: Online Resource
    ISSN: 2035-3006
    URL: Article
    DOI: 10.4084/mjhid.2015.054
    Language: Unknown
    Publisher: Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy
    Publication Date: 2015
    detail.hit.zdb_id: 2674750-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts
    Springer Science and Business Media LLC ; 2001
    In:  The Hematology Journal Vol. 2, No. 2 ( 2001), p. 70-80
    Details
    In: The Hematology Journal, Springer Science and Business Media LLC, Vol. 2, No. 2 ( 2001), p. 70-80
    Type of Medium: Online Resource
    ISSN: 1466-4860
    URL: Article
    DOI: 10.1038/sj.thj.6200095
    RVK:
    XA 46560
    Language: Unknown
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2001
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
    Ferrata Storti Foundation (Haematologica) ; 2021
    In:  Haematologica Vol. 107, No. 5 ( 2021-07-22), p. 1153-1162
    Details
    In: Haematologica, Ferrata Storti Foundation (Haematologica), Vol. 107, No. 5 ( 2021-07-22), p. 1153-1162
    Abstract: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, including one-third of cases overexpressing MYC and BCL2 proteins (double expressor lymphoma, DEL) and 5-10% of patients with chromosomal rearrangements of MYC, BCL2 and/or BCL-6 (double/triple-hit lymphomas, DH/TH). TP53 mutations are detected in 20- 25% of DEL. We report the efficacy of dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in a series of 122 consecutive patients, including DEL (n=81, 66%), DEL-MYC (n=9, 7%), DEL-BCL2 (n=13, 11%), or high-grade lymphomas (DH/TH) (n=19, 16%). Central nervous system (CNS) prophylaxis included intravenous methotrexate (n=66), intrathecal chemotherapy (IT) (n=40) or no prophylaxis (n=16). Sixty-seven patients (55%) had highintermediate or high International Prognostic Index (IPI) and 30 (25%) had high CNS-IPI. The 2-year progression-free survival (PFS) and overall survival (OS) for the entire study population were 74% and 84%, respectively. There was a trend for inferior OS for DH/TH (2-year OS: 66%, P=0.058) as compared to all the others. The outcome was significantly better for the IPI 0-2 versus IPI 3-5 (OS: 98% vs. 72%, P=0.002). DA-EPOCH-R did not overcome the negative prognostic value of TP53 mutations: 2-year OS of 62% versus 88% (P=0.036) were observed for mutated as compared to wild-type cases, respectively. Systemic CNS prophylaxis conferred a better 2-year OS (94%) as compared to IT or no prophylaxis (76% and 65%, respectively; P=0.008). DA-EPOCH-R treatment resulted in a favorable outcome in patients with DEL and DEL with single rearrangement, whereas those with multiple genetic alterations such as DEL-DH/TH and TP53 mutated cases still have an inferior outcome.
    Type of Medium: Online Resource
    ISSN: 1592-8721 , 0390-6078
    URL: Article
    DOI: 10.3324/haematol.2021.278638
    Language: Unknown
    Publisher: Ferrata Storti Foundation (Haematologica)
    Publication Date: 2021
    detail.hit.zdb_id: 2186022-1
    detail.hit.zdb_id: 2030158-3
    detail.hit.zdb_id: 2805244-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Genomic integration of HHV-6 mimicking viral reactivation after autologous stem cell transplantation
    Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy ; 2018
    In:  Mediterranean Journal of Hematology and Infectious Diseases Vol. 10, No. 1 ( 2018-02-15), p. e2018013-
    Details
    In: Mediterranean Journal of Hematology and Infectious Diseases, Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy, Vol. 10, No. 1 ( 2018-02-15), p. e2018013-
    Abstract: The monitoring of HHV-6 after allogeneic hematopoietic stem cell transplantation (HSTC) has proven to be useful in preventing life-threatening complications; however, the pathogenic role of HHV-6 after autologous HSCT is not well-characterized, although viral reactivation might be responsible for significant complications even after autologous HSCT. Here we report for the first time to our knowledge the case of a patient with genomic integration of HHV-6, presenting with high titers of HHV-6 after autologous HSCT, mimicking HHV-6 reactivation. The presence of viral DNA in the follicle bulb confirmed the genomic integration and allowed the discontinuation of the antiviral treatment to the patient.  This case might be helpful for discriminate HHV-6 reactivation from viral integration, thus avoiding unnecessary and potentially toxic antiviral therapy once the genomic integration is confirmed.
    Type of Medium: Online Resource
    ISSN: 2035-3006
    URL: Article
    DOI: 10.4084/mjhid.2018.013
    Language: Unknown
    Publisher: Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy
    Publication Date: 2018
    detail.hit.zdb_id: 2674750-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...